A major constituent in the deposit of the brain in a patient with Alzheimer's disease (AD) is
the aggregates/fibrils of amyloid-β (Aβ) peptides containing 39− 43 amino acids. The total …

Amyloid peptide oligomers and fibrils are studied as targets for therapy and diagnosis of
Alzheimer's disease. They are usually detected by amyloid incubation, but such method is …

Oligomeric amyloid-beta (Aβ) peptides are considered as the most toxic species in
Alzheimer's disease (AD). Monitoring of the Aβ aggregation profiles is critical for elucidating …

Several different monoclonal antibodies (mAbs) have been actively developed in the field of
Alzheimer's disease (AD) for basic science and clinical applications; however, the binding …

The challenges associated with performing surface plasmon resonance (SPR) based
measurements in serum and other biofluids have continued to limit the applicability of this …

The ability to directly detect Tau protein and other neurodegenerative biomarkers in human
plasma at clinically relevant concentrations continues to be a significant hurdle for the …

We analyzed the aggregation of Alzheimer's β-amyloid (1-42)(Aβ42) peptides from fresh
monomers to fully grown fibrils by using in situ surface plasmon resonance (SPR) …

Alzheimer's disease (AD) is the most common chronic, progressive neurodegenerative
disease, which affects an increasing number of elderly patients. So far, there is no cure for …

The rapid and direct detection of biomarkers in biofluids at clinically relevant concentrations
faces serious limitations to develop diagnostic criteria for neurodegenerative diseases such …

The early diagnosis of Alzheimer's disease (AD) is challenging due to the lack of reliable
methods for detecting its biomarkers in the noninvasive biopsies. We used surface plasmon …